ParinGenix Inc.

ParinGenix Inc. was founded to develop 2-O, 3-O desulfated heparin, a nonanticoagulant heparin derivative, for the treatment of inflammatory diseases. The company has advanced the drug through Phase II clinical trials for the treatment of COPD.

Investors

• Research Corporation Technologies
• CHL Medical Partners (Stamford, Conn.)
• Domain Associates LLC (Princeton, N.J.)
• Aurora Funds (Durham, N.C.)

Inventors/Founders

Thomas Kennedy, M.D.
Carolinas Medical Center